Skip to content

A Clinical Study on the Efficacy of Qifu Huang Decoction in the Treatment of Sepsis-Induced Acute Kidney Injury

A Clinical Study on the Efficacy of Qifu Huang Decoction in the Treatment of Sepsis-Induced Acute Kidney Injury

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000923
Enrollment
Unknown
Registered
2026-04-09
Start date
2026-01-01
Completion date
Unknown
Last updated
2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis-associated acute kidney injury

Interventions

Intervention Group:Administer Qifu Huang formula via oral, gastric, or jejunal feeding tube, combined with standard treatment (including antibiotics and fluid resuscitation, etc.).
Placebo group:Administer placebo combined with standard therapy (including antibiotics and fluid resuscitation, etc.) via oral, gastric, or jejunal feeding tube routes.

Sponsors

Capital Medical University Affiliated Beijing Friendship Hospital Department of Critical Care Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 95 Years

Inclusion criteria

Inclusion criteria: 1. Age = 18 years, meeting the diagnostic criteria for Sepsis-3.0; 2. Meeting the diagnostic criteria for KDIGO AKI; 3. Confirmed by a professional TCM physician through pattern identification to meet the criteria for using traditional Chinese herbal formulas; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with Chronic Kidney Disease (CKD Stage 4-5) (regular or irregular dialysis prior to ICU admission); patients with a history of kidney transplantation. 2. Patients allergic to the components of the study drug. 3. Patients who have clinically abandoned treatment or have been in the ICU for =7 days. 4. Patients where clinical judgment attributes irreversible kidney function to other factors (contrast agents, nephrotoxic drugs, urinary tract obstruction, etc.). 5. Patients suspected to have elevated Scr due to Angiotensin-Converting Enzyme Inhibitors (ACEI) or Angiotensin Receptor Blockers (ARB), with kidney function after discontinuation of ACEI/ARB. 6. Pregnant or breastfeeding women. 7. Patients participating in other drug clinical studies.

Design outcomes

Primary

MeasureTime frame
Renal Function Recovery Rate;

Secondary

MeasureTime frame
Number of days in ICU;Hospital Mortality Rate;28-day mortality rate;90-day mortality rate;Has renal function been restored after 90 days?;

Countries

China

Contacts

Public ContactRan Pang

Capital Medical University Affiliated Beijing Friendship Hospital Department of Critical Care Medicine

879080054@qq.com010-63138814

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026